Get the Stockscreener App
11.57
0.61%
0.07
Roivant Sciences Ltd stock is traded at $11.57, with a volume of 12.15M.
It is up +0.61% in the last 24 hours and up +0.70% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.50
Open:
$11.47
24h Volume:
12.15M
Relative Volume:
2.10
Market Cap:
$8.42B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
-8.6343
EPS:
-1.34
Net Cash Flow:
$-781.21M
1W Performance:
-2.28%
1M Performance:
+0.70%
6M Performance:
+7.13%
1Y Performance:
+16.16%
1-Day Range:
$11.41
$11.67
1-Week Range:
$11.41
$12.21
52-Week Range:
$9.69
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.57 | 8.42B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Barclays PLC Purchases 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Mayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant sciences executive sells common shares worth $4.97 million By Investing.com - Investing.com South Africa
Roivant sciences executive sells common shares worth $4.97 million - Investing.com
Geode Capital Management LLC Acquires 1,460,205 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Retirement Systems of Alabama - MarketBeat
Ramaswamy Urges BuzzFeed to Cut Jobs, Air More Conservative Voices - MSN
Trump administration will have financial ties to biotechs - BioCentury
State Street Corp Buys 1,118,561 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What is Leerink Partnrs' Estimate for ROIV Q3 Earnings? - MarketBeat
Several Positive Developments Lifted Roivant (ROIV) in Q3 - Insider Monkey
Edgestream Partners L.P. Buys Shares of 48,226 Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 762,953 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
MetLife Investment Management LLC Has $2.60 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant to stop lung disease drug development after trial failure - MSN
Roivant Sciences: A Biotech Growth Play With Major Ambitions (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (NASDAQ:ROIV) Holdings Cut by Melqart Asset Management UK Ltd - MarketBeat
Maven Securities LTD Purchases Shares of 400,000 Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Charles Schwab Investment Management Inc. Buys 646,627 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Phase II miss for namilumab - The Pharma Letter
Erste Asset Management GmbH Buys New Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ends Namilumab Study Due to Inefficacy - TipRanks
Roivant falls as lung disease drug fails in mid-stage study - XM
TOMS Capital Investment Management LP Invests $46.33 Million in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Thrivent Financial for Lutherans Sells 62,228 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Fmr LLC Increases Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Rubric Capital Management LP Sells 600,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Loomis Sayles & Co. L P Has $45.15 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences president Eric Venker sells $1.13 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences president Eric Venker sells $1.13 million in shares - Investing.com
Thompson Siegel & Walmsley LLC Takes $5.93 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates - MSN
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution - Yahoo Finance
Principal Financial Group Inc. Trims Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Vivek Ramaswamy's Net Worth Is 9 Figures—See How the DOGE Co-Lead Made His Millions - Yahoo Finance
Andreas Halvorsen's Recent Transaction in Roivant Sciences Ltd - GuruFocus.com
Roivant Sciences Ltd. (ROIV) Quarterly 10-Q Report - Quartzy
Vivek Ramaswamy: 10 things you ought to know about Trump's DOGE co-lead - MSN
Roivant Sciences Ltd - Reuters
Roivant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trump’s appointment of Ramaswamy sparks speculation on Korean biotech firms linked to Roivant - KBR
Who is Vivek Ramaswamy? Know about his early life, education, and role as head of the new "Department of Government Efficiency" (DOGE) - MSN
From Vadakkanchery to top US Govt post: Vivek Ramaswamy's Kerala roots - Mathrubhumi English
The Analyst Landscape: 5 Takes On Roivant Sciences - Benzinga
How Vivek Ramaswamy Became A Billionaire - Forbes
Who is Vivek Ramaswamy? What to know about Cincinnati billionaire part of Trump's Cabinet - The Cincinnati Enquirer
Vivek Ramaswamy Net Worth 2024: How He Built a Billion-Dollar Empire - Black Star News
Vivek Ramaswamy's journey from bright son of immigrants to being Donald Trump's pick - The Economic Times
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):